论文部分内容阅读
目的:探讨血清肌钙蛋白Ⅰ(CTnI)对无ST段抬高的急性冠脉综合征(NSTEACS)患者的危险分层与预后预测价值。方法:对34例NSTEACS患者,12例健康者分别测定血清CTnI,并观察住院期间主要的心血管复合事件(心脏性死亡,非致命性心肌梗死,反复缺血性心绞痛发作),随访1~12个月主要心血管事件的发生。结果:NSTEACS组血清CTnI值明显高于正常对照组(P<0.01)。NSTEACS组CTnI阳性组所测结果明显高于CTnI阴性组(P<0.01),且CTnI阳性组较CTnI阴性组的住院期间非致命性心肌梗死发生率增高,住院期与随访期反复心绞痛发作增加,总心脏性病死率也上升,且复合心血管事件也显著增多。结论:血清CTnI检测对NSTEACS患者危险分层与预后预测有重要的判断价值。
Objective: To investigate the value of serum troponin Ⅰ (CTnI) in risk stratification and prognosis of patients with non-ST segment elevation acute coronary syndrome (NSTEACS). Methods: Thirty-four patients with NSTEACS and 12 healthy controls were enrolled in this study. Serum CTnI levels were measured and the major cardiovascular events (cardiac death, non-fatal myocardial infarction and recurrent ischemic angina) during hospitalization were observed. Month of major cardiovascular events. Results: Serum CTnI in NSTEACS group was significantly higher than that in normal control group (P <0.01). The results of CTnI positive group in NSTEACS group were significantly higher than that of CTnI negative group (P <0.01), and the incidence of non-fatal myocardial infarction in hospitalized patients with CTnI positive group and CTnI negative group increased more during hospitalization and follow-up period, Total cardiac mortality also increased, and there was a significant increase in complex cardiovascular events. Conclusion: Serum CTnI test has important value in predicting the risk stratification and prognosis of patients with NSTEACS.